

RECEIVED

OFFICE
DEC 24 2003
PATENT & TRADEMARK OFFICE
FEDERAL BUREAU OF INVESTIGATION
U.S. DEPARTMENT OF JUSTICE
RECEIVED
DEC 31 2003
FBI CENTER 1800 2200

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC10244A	SERIAL NO. 09/528,978
APPLICANT R. S. OBACH		
FILING DATE March 21, 2000		GROUP 1617

U.S. PATENT DOCUMENTS												
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SPD	US	5	1	6	6	2	0	7 A	11/24/92	Smith		

FOREIGN PATENT DOCUMENTS												
DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
											YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)												
--	--	--	--	--	--	--	--	--	--	--	--	--

SPD	1	D. Quellet, et al., "Antimicro Agent and Chemo", Vol. 42, No. 12, December 1998, pages 3107-3112.
	/	MA Laurent-kenesi, et al., "Br. J. Clin Pharmacol.", PUBMED Abstract: 12959269; December 1993, 36(6) pages 531-8.
	/	N. Yasui, et al., "Pharmacogenetics", PUBMED Abstract: 9352572, October 1997, 7(5) pages 369-374.
	/	R. C. Halliday, et al., "An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems", Br. J. Clin Pharmacol., Oct. 1995, 40(4), pages 369-378, abstract (PMID: 8554939 (Medline)).
	/	S. E. Ball, et al., "Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desimipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2", British Journal of Clinical Pharmacology, Vol. 43, Issue 6, June 1997, pages 619-626, abstract (PMID: 9205822 (Medline)).
	/	S. H. Sindrup, et al., "The pharmacogenetics of codeine hypoalgesia", Pharmacogenetics, Vol. 5, Issue 6, December 1995, pages 335-346, abstract (PMID: 8845855 (Medline)).
	/	B. A. Sproule, et al., "Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence", Clinical Pharmacokinetics, Vol. 33, Issue 6, December 1997, pages 454-471, abstract (PMID: 9435993 (Medline)).
	/	J. B. Gordon, "SSRIs and St. John's Wort: possible toxicity?", American Family Physician, March 1, 1998, Vol. 57, Issue 5, pages 950-953, the whole document.
	/	Chandra Prakash, et al., "Metabolism and excretion of a new anxiolytic drug candidate, CP-93393, in healthy male volunteers", Drug Metabolism and Disposition, Vol. 26, No. 5, pages 448-455, page 453, column 2-page 454, column 1.
	/	J. S. Markowitz, et al., "Effect of St. John's Wort on Cytochrome P-450 2D6 and 3A4 Activity in Healthy Volunteers", Pharmacology Letters, January 21, 2000, Vol. 66, No. 9, pages 133-139, abstract.
SPD		F. Broly, et al., "Effect of quinidine on the dextromorphan O-demethylase activity of microsomal fractions from human liver", Br. J. Clin Pharmacol., July 1989, 28(1), pages 29-36, abstract (PMID: 2775613 (Medline)).

EXAMINER	DATE CONSIDERED
S. Jiang	3/27/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 13 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO. PC10244A

SERIAL NO. 09/528,738

(Use several sheets if necessary)

APPLICANT R. S. Obach

FILING DATE March 21, 2000

GROUP unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL ATION
					yes no

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

B. Schmidt *et al.*, "Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation", Clin. Pharmacol. Ther., 38, 618 (1985)

K. Nakamura, *et al.*, "Oxidation of Histamine H1 Antagonist Mequitazine is Catalyzed by Cytochrome P450 2D6 in Human Liver Microsomes", J. Pharmacol. Exp. Ther., 284, 437-442 (1998)

H. Kamimura *et al.*, "Identification of cytochrome P450 isozymes involved in metabolism of the α_1 adrenoceptor blocker tamsulosin in human liver microsomes", Xenobiotica, 28, 909-22 (1998)

M. Yaïch *et al.*, "In vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans", Pharmacogen., 8, 449-51 (1998)

A.E. Mutlib *et al.*, "Application of Liquid Chromatography/Mass Spectrometry in Accelerating the Identification of Human Liver Cytochrome P450 Isoforms Involved in the Metabolism of Iloperidone, J. Pharmacol. Exp. Ther., 286, 1285-93 (1998)

R. Scott Orbach, *et al.*, "Cytochrome P4502D6 Catalyzes the O-Demethylation of the Psychoactive Alkaloid Ibogaine to 12-Hydroxyibogamine", Drug Metab. Dispos., 26, 764-8 (1998).

R.L. Voorman, *et al.*, Metabolism of Delavirdine, A Human Immunodeficiency virus Type-1 Reverse Transcriptase Inhibitor, by Microsomal Cytochrome P450 in Humans, Rats, and Other Species: Probable Involvement of CYP2D6 and CYP3A, Drug Metab. Dispos., 26, 631-9 (1998).

N. Brynne *et al.*, "Influence CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine", Clin. Pharmacol. Ther., 63, 529-39 (1998)

Rinshoyakon, 29, 231-38 (1998)

Z. Desta, *et al.*, "Identification and Characterization of Human Cytochrome P450 Isoforms Interacting with Pimozide", J. Pharmacol. Exp. Ther., 285, 428-37 (1998)


W. Kishimoto *et al.*, "Metabolism of Epinastine, a Histamine H1 Receptor Antagonist, in Human Liver Microsomes in Comparison with that of Terfenadine", Res. Comm. Md. Path. Pharmacol., 98, 273-92 (1997)

JUN 13 2003

JUN 13 2003

RECEIVED

TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10244A	SERIAL NO. 09/528,798 ⁹⁷⁸
		APPLICANT R. S. Obach	
		FILING DATE March 21, 2000	GROUP unknown
320	W.D. Paar <i>et al.</i> , "Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol", 12 <i>Eur. J. Clin. Pharm.</i> , 53, 235-239 (1997)		
	E. Lessard <i>et al.</i> , "Role of CYP2D6 in the N-hydroxylation of procainamide", <i>Pharmacogenetics</i> , 7, 381-90 (1997);		
	L.Y. Lin <i>et al.</i> , "Oxidation of Methamphetamine and Methylenedioxyamphetamine by CYP2D6", <i>Drug Metab. Dispos.</i> , 25, 1059-64 (1997)		
	hangata Dehal <i>et al.</i> , "CYP2D6 Catalyzes Tamoxifen-Hydroxylation in Human Liver", <i>Cancer Res.</i> , 57, 3402-06 (1997)		
	Y. Bottiger <i>et al.</i> , "Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans", <i>Br. J. Pharm.</i> , 42, 707-11 (1996)		
	B. A. Hamelin <i>et al.</i> , "The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin", <i>Clin. Pharmacol. Ther.</i> , 60, 512-21 (1996)		
	M. F. Fromm <i>et al.</i> , "Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs", in <i>Advanced Drug Delivery Reviews</i> , 27, 171-199 (1997)		
	V. Ozdemir, <i>et al.</i> , "The Extent and Determinants of Changes in CYP2D6 and CYP1A2 Activities with Therapeutic Doses of Sertraline", <i>J. Clin. Psychopharm.</i> , 18, 55-61 (1998)		
	S.E. Ball <i>et al.</i> , Venlafaxine: <i>in vitro</i> inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2", <i>Br. J. Pharm.</i> , 43, 619-26 (1997)		
	A.D. Rodrigues, "The <i>In Vitro</i> Interaction of Dexmedetomidine with Human Liver Microsomal Cytochrome P4502D6", <i>Drug Metabolism and Disposition</i> , 25, 651-55 (1997)		
507	T. Prueksaritanont <i>et al.</i> , " <i>In Vitro</i> and <i>In Vivo</i> Evaluations of Intestinal Barriers for the Zwitterion L-767,679 and its Carboxyl Ester Prodrug L-775,318, <i>Drug Metabolism and Disposition</i> , 26, 531-39 (1998)		
	O.O. Simooya <i>et al.</i> , "Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians", <i>Br. J. Clin. Pharm.</i> , 45, 315-(1998);		
	Sebastian Härtter <i>et al.</i> , "Inhibition of dextromethorphan metabolism by moclobemide", <i>Psychopharm.</i> , 135, 22-26 (1998)		
EXAMINER  DATE CONSIDERED 10/9/03			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE